July 24, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
| Attention: Chris Edwards, Esq. |
| Division of Corporation Finance |
| Re: | IGC Pharma, Inc. Registration Statement on Form S-3 (No. 333-288785) |
Ladies and Gentlemen:
On behalf of IGC Pharma, Inc. (the “Company”), we enclose the Company’s request for acceleration of the above-referenced Registration Statement to 4:00 p.m., Eastern time, on Monday, July 28, 2025, or as soon as possible thereafter.
Please advise the undersigned of the effectiveness of the Registration Statement.
| Very truly yours, | |
| /s/ Kenneth Schlesinger | |
| Kenneth Schlesinger |
| cc: | Mr. Ram Mukunda Ms. Claudia Grimaldi |
IGC Pharma, Inc.
10224 Falls Road
Potomac, MD 20854
July 24, 2025
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
| Attention: Tim Buchmiller, Esq. |
| Division of Corporation Finance |
| Re: | IGC Pharma, Inc. Registration Statement on Form S-3 (No. 333-288785) |
Ladies and Gentlemen:
IGC Pharma, Inc. hereby requests that the effectiveness of the above-referenced Registration Statement be accelerated so that it will become effective at 4:00 p.m., Eastern time, on Monday, July 28, 2025, or as soon as possible thereafter.
| Very truly yours, | ||
| IGC PHARMA, INC. | ||
| By: | /s/ Ram Mukunda | |
| Ram Mukunda | ||
| Chief Executive Officer and President | ||